Benzinga - by Avi Kapoor, Benzinga Staff Writer.
The Dow Jones index closed higher by over 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
OPKO Health
- The Trade: OPKO Health, Inc. (NASDAQ: OPK) Chief Innovation Officer Gary Nabel acquired a total of 216,184 shares an average price of $0.93. To acquire these shares, it cost around $200,427.
- What’s Happening: OPKO Health recently priced private offering of $200 million convertible senior notes due 2029.
- What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.
- The Trade: LivePerson, Inc. (NASDAQ: LPSN) 10% owner Alexander Slusky acquired a total of 1,805,569 shares at at an average price of $3.49. To acquire these shares, it cost around $6.29 million.
- What’s Happening: LivePerson named John Sabino as CEO.
- What LivePerson Does: LivePerson Inc offers cloud-based platform solutions. It enables businesses and consumers to connect through conversational interfaces, such as in-app and mobile messaging, while leveraging bots and Artificial Intelligence (AI) to increase efficiency.
Cell MedX
- The Trade: Cell MedX Corp. (OTC: CMXC) CEO David Jeffs acquired a total of 88,959,726 shares at an average price of $0.01. The insider spent around $622,718 to buy those shares.
- What’s Happening: Cell MedX recently entered into agreements to settle debt in the aggregate amount of $1,622,693 for shares at a price of $0.007 per share for an aggregate of 231,813,310 shares of common stock.
- What Cell MedX Does: Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.